Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Anti-hyperglycaemic Drugs With a 6-month Safety Extension Period

Trial Profile

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Anti-hyperglycaemic Drugs With a 6-month Safety Extension Period

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EDITION-III
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Jun 2019 Results reporting data on patient satisfaction from EDITION 3 and BRIGHT trial presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 31 Aug 2018 Biomarkers information updated
    • 08 Dec 2017 Results of a post-hoc analysis from EDITION 1,2, and 3 studies presented at the 2017 Congress of the International Diabetes Federation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top